"Cutting edge cancer therapy developed in India"

9th June,2021

"Cutting edge cancer therapy developed in India"




Researchers from the Indian Institute of Technology (IIT) Bombay and the Tata Memorial Centre (TMC) in Mumbai have teamed up to produce an indigenously developed contemporary gene therapy for cancer treatment.

The medication, known as Chimeric Antigen Receptor T-cell (CAR-T), is a game-changer in cancer treatment, but it's excessively pricey at 3-4 crore per patient.

This technology is not currently accessible for treatment in India, and the main hurdle was developing it in a cost-effective manner so that cancer patients in India may benefit from it, according to an official statement released on Tuesday.At the Tata Memorial Hospital in Mumbai, the research team tested out CAR-T cell therapy (a type of gene therapy) for the first time last week. The Bioscience and Bioengineering Department (BSBE) of IIT-Bombay created and manufactured these CAR-T cells. The devoted efforts and partnership between IIT Bombay and TMH have resulted in a “first in India” gene therapy in an early phase pilot clinical trial. The National Biopharma Mission-BIRAC (Biotechnology Industry Research Advisory Council) of the Indian government has given the team Rs 19.15 crore to perform a first-in-human phase-1/2 clinical study using CAR-T cells.The devoted efforts and partnership between IIT Bombay and TMH have resulted in a “first in India” gene therapy in an early phase pilot clinical trial. The National Biopharma Mission-BIRAC (Biotechnology Industry Research Advisory Council) of the Indian government has given the team Rs 19.15 crore to perform a first-in-human phase-1/2 clinical study using CAR-T cells.Dr. (Surg Cdr) Gaurav Narula, Professor of Paediatric Oncology and Health Sciences at TMC, and his colleagues are conducting the clinical trials. Rahul Purwar, a BSBE professor, and his team developed the revolutionary CAR-T cells that will be used as medications. Purwar and Narula, two investigators from IIT-B, worked together on the concept, development, and thorough pre-clinical testing as part of a collaborative initiative with TMC. According to the statement, DBT supports the development of CAR-T cell technology for diseases such as acute lymphocytic leukaemia, multiple myeloma, glioblastoma, hepatocellular carcinoma, and type-2 diabetes.